Compare AbCellera Biologics Inc (ABCL) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Union Pacific Corporation — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Union Pacific Corporation trades at $281.55 (market cap $168.09B). The key difference: Union Pacific Corporation is far larger — about 71.5× AbCellera Biologics Inc's market cap, and Union Pacific Corporation pays a 1.95% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | UNP | |
|---|---|---|
Market Cap | $2.35B | $168.09B |
Sector | Health | Industrials |
52-Week High | $8.12 | $283.12 |
52-Week Low | $2.78 | $214.91 |
Enterprise Value | $1.99B | $198.56B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Union Pacific (UNP) trades at $283.12, up 0.31% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.93, and maintains robust profitability with a 29.2% net margin. Recent news highlights the ongoing merger process with Norfolk Southern and a class action lawsuit regarding environmental concerns.
Outlook remains positive with a consensus price target of $290.55, indicating potential upside. Key risks include regulatory scrutiny of the merger and legal challenges. The stock's valuation multiples are elevated, but solid cash flow and dividend growth support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
